Close

Anti-CD22 AbTCR, pCDTCR1 (AbT-ZP019)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The AbTCR fuses an antigen-binding domain from anti-CD22 (Inotuzumab) antibody with the C- terminal signaling domain of a γδTCR. More specifically, the antigen-binding domain of our AbTCR is an antibody Fab fragment, and the cellular-activation domain of consists of portions of the δ and γ chains of a γδTCR. And the vector product is designed to facilitate T-cell cytotoxicity with low cytokine release and is used in Acute lymphoblastic leukemia (ALL).

Specific Inquiry

  • Size:
  • Form:
  Add to Cart

Details

  • Target
  • CD22
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Acute lymphoblastic leukemia (ALL)
  • Vector Name
  • pCDTCR1
  • Vector length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • Fab-γδ TCR
  • Discription of Signaling Cassetes
  • Fab-γδ TCR
    In the majority of T cells, the TCR consists of an α chain and a β chain, whereas in 1–5% of T cells the TCR consists of a gamma (γ) and a delta (δ) chain. However, there were technical hurdles with the mispairing with the T-cell's endogenous α and β TCR chains and having to express two synthetic molecules in the same cell. Instead of previous designs that were built on αβ chains of the TCR, our AbTCR platform avoids mispairing with the T cell's endogenous αβTCR by using the transmembrane and intracellular domains from the γδTCR. Similar to the exogenously-expressed TCR in TCR-T cells, our AbTCR engages the endogenous CD3 complex to initiate T-cell activation. However, since the γδTCR chains do not bind with the TCRs in αβ T-cells, AbTCR avoids the mispairing challenge of traditional αβTCR-based synthetic receptors.
    In addition, by employing a Fab as the antigen-binding domain, the AbTCR can be used to target either peptide-MHC complexes or cell surface antigens by using TCR-mimic or conventional antibodies respectively.
    Overall, the AbTCR design couples the antigen-binding utility of an antibody to the endogenous TCR activation pathways.

Target

  • Clone
  • Inotuzumab
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • membrane spanning 4-domains A1
  • Synonyms
  • B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; BA0185

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD22 (Inotuzumab) h(Fab-γδ TCR) Antibody T Cell Receptor, pCDTCR1 (AbT-ZP019). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.